Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Emily Dworkin"'
Autor:
Gregory W. Roloff, Frank Wen, Aubrianna Ramsland, Andrew S. Artz, Satyajit Kosuri, Wendy Stock, Olatoyosi Odenike, Richard A. Larson, Hongtao Liu, Lucy A. Godley, Michael J. Thirman, Anand A. Patel, Christopher K. Daugherty, Adam S. DuVall, Mariam T. Nawas, Emily Dworkin, Geoffrey D. Wool, Sandeep Gurbuxani, Carrie Fitzpatrick, Jeremy P. Segal, Peng Wang, Michael W. Drazer
Publikováno v:
Haematologica, Vol 108, Iss 8 (2023)
Externí odkaz:
https://doaj.org/article/1d4372d7237e4993adbe87d1b89ac577
Autor:
Anand Ashwin Patel, Joseph Heng, Emily Dworkin, Sarah Monick, Benjamin A. Derman, Adam S. DuVall, Sandeep Gurbuxani, Satyajit Kosuri, Hongtao Liu, Michael Thirman, Lucy A. Godley, Olatoyosi Odenike, Richard A. Larson, Wendy Stock
Publikováno v:
eJHaem, Vol 2, Iss 3, Pp 413-420 (2021)
Abstract Although acute lymphoblastic leukemia (ALL) is most common in pediatric and adolescent and young adult (AYA) patients, 20% of cases are diagnosed in patients ≥ 55 years old. Use of intensive pediatric regimens in AYA populations has demons
Externí odkaz:
https://doaj.org/article/1b4a824c4e394577afc07f08ab0b8c0a
Publikováno v:
Aggression and Violent Behavior. 71:101839
Autor:
Gregory W. Roloff, Frank Wen, Aubrianna Ramsland, Andrew S. Artz, Satyajit Kosuri, Wendy Stock, Olatoyosi Odenike, Richard A. Larson, Hongtao Liu, Lucy A. Godley, Michael J. Thirman, Anand A. Patel, Christopher K. Daugherty, Adam S. DuVall, Mariam T. Nawas, Emily Dworkin, Geoffrey D. Wool, Carrie Fitzpatrick, Jeremy P. Segal, Peng Wang, Michael W. Drazer
The treatment of acute myeloid leukemia (AML) has been enhanced by the development and regulatory approval of a series of novel agents, including midostaurin and gilteritinib (FLT3 inhibitors), venetoclax (BCL2 inhibitor), ivosidenib (IDH1 inhibitor)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be6dffeb4a8f8b493f983208737450e5
https://doi.org/10.1101/2022.09.15.22279953
https://doi.org/10.1101/2022.09.15.22279953
Autor:
Gregory W. Roloff, Andrew S. Artz, Wendy Stock, Olatoyosi Odenike, Emily Dworkin, Geoffrey D. Wool, Carrie Fitzpatrick, Jeremy Segal, Peng Wang, Michael W. Drazer
Publikováno v:
Blood. 140:11727-11728
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 38:152-159
Objective Oritavancin is a lipoglycopeptide antibiotic approved for use in acute bacterial skin and skin structure infections as a single 1200-mg parenteral dose. Because of oritavancin's long half-life and broad gram-positive activity, interest in i